Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company's President and CEO, John Celebi, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 10:40 a.m. ET.
Interested parties can access the presentation webcast through the Investors section of Sensei's website. The replay will remain available for approximately 90 days after the event, and registration for the webcast is currently open.
Sensei Biotherapeutics (Nasdaq: SNSE), un'azienda biotecnologica in fase clinica specializzata in terapie antitumorali di nuova generazione, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale delle Scienze della Vita di Oppenheimer. Il Presidente e CEO dell'azienda, John Celebi, terrà una presentazione durante l'evento virtuale il martedì 11 febbraio 2025, alle 10:40 a.m. ET.
Le parti interessate possono accedere al webcast della presentazione tramite la sezione Investitori del sito web di Sensei. La registrazione per il webcast è attualmente aperta e la riproduzione sarà disponibile per circa 90 giorni dopo l'evento.
Sensei Biotherapeutics (Nasdaq: SNSE), una compañía biotecnológica en etapa clínica especializada en terapias contra el cáncer de próxima generación, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Vida de Oppenheimer. El Presidente y CEO de la empresa, John Celebi, realizará una presentación en el evento virtual el martes 11 de febrero de 2025, a las 10:40 a.m. ET.
Las partes interesadas pueden acceder al webcast de la presentación a través de la sección de Inversores del sitio web de Sensei. La repetición estará disponible durante aproximadamente 90 días después del evento, y la inscripción para el webcast ya está abierta.
Sensei Biotherapeutics (Nasdaq: SNSE), 차세대 암 치료제에 전문화된 임상 단계 생명공학 회사가 Oppenheimer의 제35회 연례 생명 과학 회의에 참여한다고 발표했습니다. 회사의 사장이자 CEO인 John Celebi는 2025년 2월 11일 화요일 오전 10시 40분 ET에 가상 이벤트에서 발표를 진행할 예정입니다.
관심 있는 당사자는 Sensei 웹사이트의 투자자 섹션을 통해 프레젠테이션 웹캐스트에 접근할 수 있습니다. 이벤트 후 약 90일 동안 다시보기 가능합니다. 웹캐스트 등록은 현재 열려 있습니다.
Sensei Biotherapeutics (Nasdaq: SNSE), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies anticancéreuses de nouvelle génération, a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie. Le Président et CEO de l'entreprise, John Celebi, fera une présentation lors de l'événement virtuel le mardi 11 février 2025 à 10h40 ET.
Les parties intéressées peuvent accéder au webcast de la présentation via la section Investisseurs du site web de Sensei. La rediffusion sera disponible pendant environ 90 jours après l'événement, et l'inscription pour le webcast est actuellement ouverte.
Sensei Biotherapeutics (Nasdaq: SNSE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf moderne Krebstherapien spezialisiert hat, hat seine Teilnahme an der 35. Jahrestagung für Gesundheits- und Lebenswissenschaften von Oppenheimer angekündigt. Der Präsident und CEO des Unternehmens, John Celebi, wird am Dienstag, den 11. Februar 2025, um 10:40 Uhr ET eine Präsentation bei der virtuellen Veranstaltung halten.
Interessierte Parteien können über den Investorenbereich der Website von Sensei auf den Webcast der Präsentation zugreifen. Die Wiederholung wird etwa 90 Tage nach der Veranstaltung verfügbar sein, und die Registrierung für den Webcast ist derzeit geöffnet.
- None.
- None.
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.
A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sensei Biotherapeutics (SNSE) presenting at Oppenheimer's Healthcare Conference 2025?
How can investors watch Sensei Biotherapeutics' (SNSE) Oppenheimer Conference presentation?
How long will the SNSE Oppenheimer Conference presentation replay be available?
What is the format of Oppenheimer's 35th Annual Healthcare Conference featuring SNSE?
